key: cord-0897526-msovhoui authors: Tozetto-Mendoza, Tania Regina; Kanunfre, Kelly Aparecida; Vilas-Boas, Lucy Santos; Sanchez Espinoza, Evelyn Patricia; Paião, Heuder Gustavo Oliveira; Rocha, Mussya Cisotto; de Paula, Anderson Vicente; de Oliveira, Maura Salaroli; Zampelli, Daniella Bosco; Vieira, José Mauro; Buss, Lewis; Costa, Silvia Figueiredo; Sabino, Ester Cerdeira; Witkin, Steven S.; Okay, Thelma Suely; Mendes-Correa, Maria Cassia title: NUCLEOPROTEIN-BASED ELISA FOR DETECTION OF SARS-CoV-2 IgG ANTIBODIES: COULD AN OLD ASSAY BE SUITABLE FOR SERODIAGNOSIS OF THE NEW CORONAVIRUS? date: 2021-01-13 journal: J Virol Methods DOI: 10.1016/j.jviromet.2021.114064 sha: c0c67f1d8ac65ebcb5f68732f1868b634faaf957 doc_id: 897526 cord_uid: msovhoui OBJECTIVES: We evaluated the performance of a nucleoprotein-based enzyme-linked immunosorbent assay (ELISA) for detection of IgG antibodies to SARS-CoV-2. METHODS: The ELISA was based on serum IgG reactivity to a 46-kDa protein derived from the recombinant SARS-CoV2 nucleoprotein. Assay sensitivity was assessed using serum samples from 134 COVID-19 confirmed cases obtained > 15 days after symptom onset. Specificity was determined by testing sera from 94 healthy controls. Cross-reactivity was evaluated with sera from 96 individuals with previous dengue or zika virus-confirmed infections, with 44 sera from individuals with confirmed infections to other respiratory viruses or with bacterial and fungal infections that cause pneumonia and with 40 sera negative for SARS-CoV-2 nucleoprotein by commercial ELISA kits. RESULTS: The majority of subjects were male and> 60 years old. Assay sensitivity was 90.3% (95% confidence interval 84.1% - 94.2%) and specificity was 97.9% (92.6% - 99.4%). There was no cross-reactivity with sera from individuals diagnosed with dengue, zika virus, influenza virus, rhinovirus, adenovirus, respiratory syncytial virus, seasonal coronavirus, Mycobacterium tuberculosis, Staphylococcus (S. aureus and coagulase-negative), Streptococcus pneumoniae, Klebsiella pneumoniae and the fungus Aspergillus fumigatus. The level of concordance of our test with results from commercial ELISA kits was 100%. CONCLUSION: The nucleoprotein-based ELISA was specific for detection of IgG anti-nucleoprotein antibodies to SARS-CoV-2.. It utilizes a frequently employed low expense assay protocol and is easier to perform than other currently available commercial SARS-CoV2 antibody detection tests. Conclusion: The nucleoprotein-based ELISA was specific for detection of IgG antinucleoprotein antibodies to SARS-CoV-2.. It utilizes a frequently employed low expense assay protocol and is easier to perform than other currently available commercial SARS-CoV2 antibody detection tests. KEYWORDS: SARS-CoV-2, COVID-19, IgG antibody, Nucleoprotein antigen, ELISA. In late 2019, the Severe Acute Respiratory Syndrome -Coronavirus-2 Virus (SARS-CoV-2), the cause of Coronavirus Infectious Disease-2019 (COVID-19), emerged in China and subsequently rapidly spread worldwide within a few months [1] . The ability to accurately determine who is infected with this virus is a critical step in achieving control of this pandemic. Diagnostic tests for COVID-19 fall into two main categories: molecular tests that detect viral J o u r n a l P r e -p r o o f RNA, and serological assays that detect anti-SARS-CoV-2 specific immunoglobulins. Analysis of nasopharyngeal and oropharyngeal secretions for viral RNA by reverse transcriptasepolymerase chain reaction (RT-PCR) is the gold standard for diagnosis of acute COVID-19 [1] . Serological assays, while more limited than RT-PCR in detecting SARS-CoV-2 infection at its initial stage, is easier to perform and much less expensive. Determination of IgG-positivity complements molecular testing by confirming exposure and identifying the magnitude of the immune response in infected individuals [2, 3] . Serological testing for SARS-CoV-2 IgG antibodies has been recommended in the following situations: screening of recovered COVID-19 patients for convalescent plasma donation, for population seroprevalence studies, and for monitoring the immune response of candidate COVID-19 vaccines [3] . The aim of the present study was to evaluate the performance of a classic protocol-based ELISA to detect SARS-CoV-2 IgG anti-nucleoprotein antibodies. Sera from individuals admitted to the hospital for suspected COVID-19 infection were assayed. The nucleoprotein was chosen as the target of the assay since it is an immunodominant antigen and consistently employed to detect antibodies against other coronaviruses in both humans and animals [4 -6] . This was a cross-sectional diagnostic accuracy study in which a SARS-CoV-2 serodiagnosis protocol was evaluated. All control samples had been stored at -80 o C and previously unthawed aliquots were tested. The protocol was performed using a qualitative nucleoprotein-based ELISA to detect were considered positive if the RI value was ≥ 1. Categorical variables were summarized as percentages, and continuous variables as median and interquartile ranges. Sensitivity and specificity were calculated following standard guidelines; 95% confidence intervals (95% CI) were calculated by the exact binomial method. To evaluate the statistical hypothesis, we used the Chi-square test or the Fisher exact test when appropriate (n< 5) for categorical variables, or the Wilcoxon rank sum for continuous variables. All analyses were performed using the R software for windows statistical computing, version 3.6.3. symptom onset to serology collection) of the study subjects, divided by the presence or absence of IgG anti-nucleoprotein antibodies is shown in Table 1 . There were no differences between J o u r n a l P r e -p r o o f seropositive and seronegative cases in these parameters by univariate analysis. In both groups, the majority of subjects were male, > 60 years of age and were admitted to an intensive care unit. The mean time from onset of symptoms to blood collection was between 22-27 days. Table 1 3.2 Assay performance Assay performance of the nucleoprotein-based ELISA to detect SARS-CoV-2 IgG antibodies is presented in Fig. 1 In this study, we confirmed the validity of a nucleoprotein-based ELISA for detection of SARS-CoV-2 IgG antibodies in sera obtained >15 days from symptom onset. This time period was chosen since a prior study demonstrated that the median time for IgG anti-SARS-CoV-2 appearance was 14 days after the onset of symptoms [7] . The specificity of our ELISA was 97.9%, which is comparable to other assays with a similar format [2, [8] [9] [10] . There were no false positives when testing 44 sera from individuals with vaccine-induced antibodies to influenza viruses, or who had severe acute respiratory syndrome or pneumonia due to other causes. In addition, we did not observe any cross-reactivity with sera from individuals with a history of infection with common cold coronaviruses such as HCoV-229E, -NL63, -OC43 and -HKU1. This paralleled findings obtained with other widely used SARS-CoV-2 serological assays [8, 16] . Different seasonal coronaviruses have been detected by RT-PCR with a frequency varying from 1.5 to 11% among patients presenting with respiratory infection in different regions in Brazil [11] [12] [13] [14] [15] . One study has reported a 10% crossreactivity with SARS-CoV-2 among sera from healthy blood donors with a history of seasonal coronaviruses This was attributed to antibody binding to conserved epitopes in the nucleocapsid or spike proteins [17] . While a potential low level cross-reaction between IgG antibodies to the seasonal coronavirus and to the pandemic SARS-CoV-2 virus is possible and needs to be considered, this is of minor concern in the epidemiological context of the Covid pandemic [8, 17, 18] . In countries like Brazil, where dengue fever and other arboviruses are endemic problems, the possibility of cross-reactions with SARS-CoV-2 could be a challenge [19] [20] [21] [22] . Although these arboviruses do not cause respiratory disease, they can be difficult to distinguish from COVID-19 as both can elicit similar extra-pulmonary manifestations such as fever, cutaneous J o u r n a l P r e -p r o o f rash and conjunctivitis. We tested 96 serum samples from patients with RT-PCR-confirmed dengue (n=76) or zika infections (n=20), collected between 2010 and 2019 and did not observe any cross-reactivity. The limitations of our study must be considered. Most patients in the present study (85.8%) were hospitalized and elderly, suggesting that their infections were severe. Previous studies have suggested that the magnitude of the antibody response to SARS-CoV-2 was related to clinical severity [23] . We cannot comment, therefore, on the sensitivity of our assay to detect IgG anti-nucleoprotein antibodies in mildly symptomatic or asymptomatic infected individuals. Similarly, limitations of our sera collection do not allow us to estimate the sensitivity of our ELISA to detect antibodies at < 15 days or >50 days after the onset of symptoms. It is important to emphasize that the duration and persistence of circulating antibodies against SARS-CoV-2 have not yet been established for most tests that are currently used [8] . Therefore, this limitation is not exclusive to our protocol. Our findings on sex are compatible with several studies reporting that the number of COVID-19 cases and their severity and lethality are higher in men compared to women [24] [25] [26] . Unfortunately, we also were unable to obtain information on clinical outcome of the studied cases. Despite these limitations, our ELISA has several advantages that should be highlighted. The sensitivity and specificity of our ELISA is high and equivalent to that of commercial kits or other in-house assays [2, [8] [9] [10] . Our assay is technically easy to perform and can be implemented without the need for specialized equipment. This may be advantageous in resource-restricted areas where diagnostic capacity is limited. In addition, the cost of analysis by our ELISA is significantly lower when compared to that of commercial tests. An ELISA format also allows for the testing of large numbers of suspected cases in a short period of time. In Brazil, a country J o u r n a l P r e -p r o o f where the number of COVID-19 cases has been rapidly rising, this ELISA assay would be of value to clarify aspects related to the spread of the infection in the community and to establish optimal policies to fight the epidemic. In conclusion, our nucleoprotein-based ELISA to detect IgG antibodies to SARS-CoV-2 is a specific and sensitive test to determine exposure to this virus two weeks from the onset of symptoms. It is a suitable and less expensive alternative to the serological tests that are currently available. The study was approved by the Hospital das Clínicas -University of São Paulo (HC- No.:30419620.1.0000.0068 and 30701920200000068, respectively). J o u r n a l P r e -p r o o f The proximal origin of SARS-CoV-2 Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19 The Role of Antibody Testing for SARS-CoV-2: Is There One Long-Term Persistence of IgG Antibodies in SARS-CoV Infected Healthcare Workers. medRxiv Recombinant nucleocapsid protein-based enzymelinked immunosorbent assay for detection of antibody to turkey coronavirus Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) Cochrane COVID-19 Diagnostic Test Accuracy Group. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications Viral and atypical bacterial detection in acute respiratory infection in children under five years Human coronavirus and severe acute respiratory infection in Southern Brazil. Pathog Glob Health High incidence of rhinovirus infection in children with community-acquired pneumonia from a city in the Brazilian pre-Amazon region Human coronavirus alone or in co-infection with rhinovirus C is a risk factor for severe respiratory disease and admission to the pediatric intensive care unit: A one-year study in Southeast Brazil Typical epidemiology of respiratory virus infections in a Brazilian slum Comparison of different serological assays for SARS-CoV-2 in real life Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans High prevalence of pre-existing serological cross-reactivity againstSARS-CoV-2 in sub-Sahara Africa Dengue antibodies can cross-react with SARS-CoV-2 and vice versa-Antibody detection kits can give false-positive results for both viruses in regions where both COVID-19 and Dengue Covert COVID-19 and false-positive dengue serology in Singapore Potential antigenic cross-reactivity between SARS-CoV-2 and Dengue viruses COVID-19 and dengue fever: A dangerous combination for the health system in Brazil Beyond the Spike: identification of viral targets of the antibody response to SARS-CoV-2 in COVID-19 patients. medRxiv 2020.04.30 Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Health Sex and Gender Differences in Health: What the COVID-19 Pandemic Can Teach Us Disparities in Age-specific Morbidity and Mortality From SARS-CoV-2 in China and the Republic of Korea We thank all staff from Laboratory of Virology, Institute of Tropical Medicine, School of This study was supported by a Research Grant from Clinical Hospital, University of São Paulo, Brazil. All authors declare that there are no conflicts of interest.